AstraZeneca to power Swedish facilities with wind energy

Norwegian power company Statkraft AS has reached a 10-year deal to supply 200 GWh of wind power annually to UK pharma company AstraZeneca’s (LON:AZN) research and manufacturing facilities in Sweden.

The power purchase agreement (PPA) is based on the commissioning of three new wind farms in Stromstad and Arjang, western Sweden. The sites are owned by local wind power company Rabbalshede Kraft which will also be their operator, according to a statement published on Wednesday.

Subscribe for Renewables Now's Corporate PPA Newsletter here for free!

The agreed electricity supply, totalling 2 TWh for the entire period, will be enough to meet 80% of the electricity needs of the British firm’s research site in Gothenburg and its factory in Sodertalje.

The deal with Statkraft will advance AstraZeneca’s goal of halving its entire value chain Scope 3 emissions by 2030.